BR0205970A - Modulação favorável da qualidade de vida relacionada à saúde e a qualidade ajustada ao tempo de progressão da doença relacionada à saúde em pacientes com c ncer de próstata - Google Patents

Modulação favorável da qualidade de vida relacionada à saúde e a qualidade ajustada ao tempo de progressão da doença relacionada à saúde em pacientes com c ncer de próstata

Info

Publication number
BR0205970A
BR0205970A BR0205970-3A BR0205970A BR0205970A BR 0205970 A BR0205970 A BR 0205970A BR 0205970 A BR0205970 A BR 0205970A BR 0205970 A BR0205970 A BR 0205970A
Authority
BR
Brazil
Prior art keywords
health
quality
life
time
progression
Prior art date
Application number
BR0205970-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Amitabh Singh
Robert J Padley
Talat Ashraf
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/832,752 external-priority patent/US20030022811A1/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BR0205970A publication Critical patent/BR0205970A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0205970-3A 2001-04-11 2002-04-11 Modulação favorável da qualidade de vida relacionada à saúde e a qualidade ajustada ao tempo de progressão da doença relacionada à saúde em pacientes com c ncer de próstata BR0205970A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/832,752 US20030022811A1 (en) 2001-04-11 2001-04-11 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
US11848602A 2002-04-08 2002-04-08
PCT/US2002/011397 WO2002085351A1 (en) 2001-04-11 2002-04-11 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer

Publications (1)

Publication Number Publication Date
BR0205970A true BR0205970A (pt) 2003-09-30

Family

ID=26816420

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0205970-3A BR0205970A (pt) 2001-04-11 2002-04-11 Modulação favorável da qualidade de vida relacionada à saúde e a qualidade ajustada ao tempo de progressão da doença relacionada à saúde em pacientes com c ncer de próstata

Country Status (10)

Country Link
EP (1) EP1379238A1 (enExample)
JP (1) JP2005503339A (enExample)
CN (1) CN1514727A (enExample)
AR (1) AR033465A1 (enExample)
BR (1) BR0205970A (enExample)
CA (1) CA2442591A1 (enExample)
IL (1) IL158071A0 (enExample)
MX (1) MXPA03009277A (enExample)
PE (1) PE20021032A1 (enExample)
WO (1) WO2002085351A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
WO2004100991A1 (en) * 2003-05-15 2004-11-25 Universite Catholique De Louvain Use of endothelin-1 antagonists for improving cancer therapy
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
WO2007133796A2 (en) * 2006-05-15 2007-11-22 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
CA2904447C (en) 2007-08-22 2017-01-03 Abbvie Deutschland Gmbh & Co Kg Therapy for complications of diabetes
WO2023011596A1 (zh) * 2021-08-05 2023-02-09 中国药科大学 酰胺类化合物及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200101234T2 (tr) * 1997-08-04 2002-06-21 Abbott Laboratories Endotelin antagonistleri.

Also Published As

Publication number Publication date
CA2442591A1 (en) 2002-10-31
EP1379238A1 (en) 2004-01-14
CN1514727A (zh) 2004-07-21
JP2005503339A (ja) 2005-02-03
AR033465A1 (es) 2003-12-17
WO2002085351A1 (en) 2002-10-31
MXPA03009277A (es) 2004-03-10
PE20021032A1 (es) 2002-11-12
IL158071A0 (en) 2004-03-28

Similar Documents

Publication Publication Date Title
DK1992695T3 (da) Lectin-transmembran-antigen af type C udtrykt i human prostatacancer og avendelser deraf
ATE515235T1 (de) Instrumentenaufbau zur verwendung in der wirbelsäulenchirurgie
CY1106285T1 (el) Χρηση αναστολεων της τυροσινης κινασης του egfr για τη θepαπεια του καρκινου του μαστου
DE60320003D1 (de) Führungsblock zur verwendung in der chirurgie
AU2001228767A1 (en) Forceps useful for intrabody guiding and/or positioning of medical instrument
BRPI0411200A (pt) método de tratamento de cáncer, métodos de tratamento de paciente humano, artigo industrializado e kit de tratamento de cáncer
ATE400813T1 (de) Tumormarker für frühes krebsstadium
DE69920178D1 (de) Super-elastische gebogene hohlnadel zur medizinischen verwendung
ATE342702T1 (de) Zwischenwirbelfusionsimplantat sowie instrument zur platzierung und distraktion des implantates
EP0772456A4 (en) DIAGNOSIS AND TREATMENT OF CELL PROLIFERATIVE DISEASES WITH THE PARTICIPATION OF CLONAL MACROPHAGES
CY1110029T1 (el) Γονιδιο που εκφραζεται στον καρκινο του προστατη
AU2002239491A1 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
BR0205970A (pt) Modulação favorável da qualidade de vida relacionada à saúde e a qualidade ajustada ao tempo de progressão da doença relacionada à saúde em pacientes com c ncer de próstata
PT981348E (pt) Utilizacao de levobupivacaina em cirurgia pediatrica
CY1115407T1 (el) Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων
GB0305575D0 (en) Novel compounds
AU2002350950A1 (en) Compounds for imaging alzheimer's disease
EP1575993A4 (en) METHOD FOR TREATING PATIENTS AND IDENTIFYING THERAPEUTICS
DE60224299D1 (de) Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor
IT1278858B1 (it) Strumentario per il trattamento di fratture articolari della caviglia
PL367707A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
PT585801E (pt) Proteina tipo caderina relacionada com osso e processo para a sua producao
AU2003250912A1 (en) Agents and methods for diagnosis and therapy of cancer and cancer risk assessment
BRPI0408322A (pt) uso de um fibrato e orlistat para o tratamento da obesidade
ITBO20030261A1 (it) Unita'di irraggiamento luminoso per diagnosi e cura di problemi cutanei.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A(S) 9A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2103 DE 26/04/2011.